Researchers Evaluate Cost-Effectiveness of Genetic Screening to Guide Initial HIV Treatment

September 18, 2008

A major study from a team of researchers from Weill Cornell Medical College and Massachusetts General Hospital has found that a recent change to HIV-treatment guidelines recommending genetic screening is cost-effective under certain conditions. The new recommendation suggests conducting a genetic screening test prior to prescribing the drug abacavir, one of the preferred first-line drugs for the treatment for HIV-infected adults.

"The guideline change represents one of the first situations in which a genetic test has been recommended for use in clinical practice to guide drug selection that will affect treatment decisions for thousands of patients each year," says lead author Dr. Bruce R. Schackman, associate professor of public health and chief of the Division of Health Policy in the Department of Public Health at Weill Cornell Medical College. "While the guidelines now recommend that physicians order this new test before prescribing abacavir, policy makers and insurers want to know whether the additional cost of the test is appropriate compared with not testing and using a different drug."

The study appears in the latest online issue of the journal AIDS.

The study findings provide guidance for policy makers in response to changes earlier this year in the U.S. Department of Health and Human Services' (DHHS) clinical guidelines for HIV treatment. A recent FDA-approved change in the abacavir drug label warns that it can cause a hypersensitivity reaction, especially in patients who carry a particular genetic variation (the HLA-B*5701 allele) that can be identified by the genetic test. Severe hypersensitivity reactions are very rare, but affect multiple organs and can be serious enough to cause hospitalization or death.

Dr. Schackman, Dr. Paul E. Sax, clinical director of the HIV Program and Division of Infectious Diseases at Brigham and Women's Hospital, and Dr. Kenneth A. Freedberg, director of Epidemiology and Outcomes Research at the Partners AIDS Research Center/Massachusetts General Hospital (PARC/MGH), collaborated on the study with Callie Scott and Drs. Rochelle P. Walensky and Elena Losina of PARC/MGH. Drs. Walensky and Losina are also affiliated with Brigham and Women's Hospital, and Drs. Freedberg and Losina are also affiliated with Boston University School of Public Health.

The authors determined that genetic testing for HLA-B*5701 is cost-effective, but only if abacavir-based treatment is as effective among those testing negative for the genetic variation as not testing and initiating treatment with tenofovir, another preferred first-line drug. In both cases, the drugs were assumed to be part of a "cocktail" that includes the drug efavirenz, which is commonly used in treating new HIV patients, and one other drug. Both abacavir and tenofovir are considered effective when used in this way, but no clinical trial results have been published that directly compare using these drugs in patients newly initiating HIV treatment. Separate "head-to-head" clinical trials that include this comparison are currently being conducted by the federally funded AIDS Clinical Trials Group and by GlaxoSmithKline, the manufacturer of abacavir.

Critically, genetic testing was found to be cost-effective based on published drug prices in the United States, where abacavir-based treatment costs less than tenofovir-based treatment, and based on Medicare reimbursement rates for the genetic test. Actual costs for drugs and tests vary by insurer and laboratory, and at lower tenofovir prices or higher test costs the genetic testing strategy was no longer cost-effective.

The authors used a computer simulation model to project the treatment outcomes and HIV medical care costs for patients initiating treatment with and without genetic testing. They used data from previous studies to project the likelihood of developing serious or mild side effects on each drug and substituting an alternative drug, and considered the implications of drug selections for subsequent HIV treatment decisions. Cost-effectiveness ratios were reported as cost per quality-adjusted life year.

"We found that genetic testing has a cost-effectiveness ratio of $36,700 per quality-adjusted life year," says Dr. Freedberg. "In the U.S., this cost-effectiveness ratio is below commonly accepted thresholds for medical interventions that are delivering 'value for money.' In other words, based on available evidence, physicians using the test are making good decisions both for their individual patients and for society."

"With a negative result on the genetic screening test, both patient and physician can feel more confident about prescribing abacavir," says Dr. Sax. "This allows them to preserve alternative drugs as future options and can help save the health care system money by using a lower-priced drug."

The study was supported in part by the National Institute of Allergy and Infectious Diseases and the National Institute on Drug Abuse.

Weill Cornell Medical College

---

---

	HIV/AIDS Treatment Drugs (Understanding Drugs) by Brigid M. Kane (Author), David J. Triggle (Editor)
	Nutrition and HIV: A New Model for Treatment by Mary Romeyn M.D. (Author) Treating HIV with Nutrition Nutrition and HIV addresses the issues of nutrition and HIV from the perspective of the patient as well as the physician. Everyone who is interested in the problems of--and solutions to--nutritional therapy in HIV owes it to themselves to read this book. --Paul A. Volberding, M.D., director, Center for AIDS Research, San Francisco This reference book offers a sound nutritional model for sustaining and improving quality of life for HIV positive men and women. It outlines an easy-to-follow program for the prevention and treatment of weight loss--a common problem that if left untreated could lead to serious health decline or even death.
	HIV/AIDS TREATMENT STRATEGIES -- Second Edition by Amazon There are various reasons for taking an interest in the treatment of HIV/ATDS. Unfortunately, AIDS has no consolidated cure at the moment. Medical science still resorts to available treatment options. In seven chapters, this book has been designed to help people seek information about treatment strategies for HIV/AIDS. These include: a general introduction to HIV/AIDS antiretroviral therapy (ART) dynamics of ARV drugs merits and demerits of ARV drugs revival of immune systems in HIV infection foundations of immunosuppression hints for the HIV-positive The book also includes details of websites for further research, review questions for those preparing for coursework or examinations, a glossary of terms and an index. By explaining a complex disease...
	PRIMARY HIV INFECTION: Early diagnosis and treatment are critical to outcome (Postgraduate Medicine) by JTE Multimedia It is now apparent that early identification of primary HIV infection is important, because events occurring in early disease may predict how fast a patient progresses to AIDS. However, as Dr Schacker points out, diagnosis is not easy at this stage. This article describes clinical features and laboratory tests to help primary care physicians make a timely diagnosis and discusses current recommendations for therapy. Original Publication Date: October 1997
	Cognitive-Behavioral Stress Management for Individuals Living with HIV: Facilitator Guide (Treatments That Work) by Michael H. Antoni (Author), Gail Ironson (Author), Neil Schneiderman (Author) For individuals living with HIV, stress can have a critical impact on emotional and physical well-being. Many HIV-infected individuals feel a loss of control over their lives, experience social isolation, and may suffer from anxiety and depression. Stress has been shown to decrease immune functioning, which is a significant concern for HIV-infected individuals. Written by the developer of the treatment, this manual presents an empirically supported, group treatment program that teaches HIV-infected individuals how to manage their stress. This comprehensive Cognitive-Behavioral Stress Management (CBSM) program combines stress management with relaxation training. Each group meeting introduces a new relaxation method, such as progressive muscle relaxation, imagery, and meditation....
	The HIV treatment pendulum.(Editorial): An article from: Internal Medicine News by Diane V. Havlir (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on March 15, 2003. The length of the article is 873 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: The HIV treatment pendulum.(Editorial) Author: Diane V. Havlir Publication: Internal Medicine News (Magazine/Journal) Date: March 15, 2003 Publisher: International Medical News Group Volume: 36 Issue: 6 Page: 10(1) Article Type: Editorial Distributed by Thomson...
	Panel releases updated HIV treatment guidelines.(Across Specialties): An article from: Clinical Psychiatry News by Sharon Worcester (Author) This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on November 1, 2004. The length of the article is 640 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Panel releases updated HIV treatment guidelines.(Across Specialties) Author: Sharon Worcester Publication: Clinical Psychiatry News (Magazine/Journal) Date: November 1, 2004 Publisher: International Medical News Group Volume: 32 Issue: 11 Page: 63(1) Distributed by Thomson...
	Drug resistance factors into HIV treatment failures.(Practice Trends): An article from: OB GYN News by Heidi Splete (Author) This digital document is an article from OB GYN News, published by Thomson Gale on November 1, 2005. The length of the article is 594 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Drug resistance factors into HIV treatment failures.(Practice Trends) Author: Heidi Splete Publication: OB GYN News (Magazine/Journal) Date: November 1, 2005 Publisher: Thomson Gale Volume: 40 Issue: 21 Page: 45(1) Distributed by Thomson...
	HIV/AIDS Treatment Strategies by S D Browne-Umar (Author) There are various reasons for taking an interest in the treatment for HIV/AIDS. Unfortunately, AIDS has no cure at the moment. But in the absence of a cure, medical science resorts to available treatment options. In seven chapters, this handy book has been designed to help people seek information about treatment strategies for HIV/AIDS. These include: A general introduction to HIV/AIDS, antiretroviral therapy (ART), dynamics of ARV drugs, merits and demerits of ARV drugs, revival of immune systems in HIV infection, foundations of immunosuppression, hints for the HIV-positive. The book also includes details of websites for further research, review questions for those preparing for coursework or examinations, a glossary of terms and an index. By explaining a complex disease as one that can...
	Group therapy can improve viral load in HIV.(Infectious Diseases): An article from: Internal Medicine News by Damian McNamara (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on February 15, 2005. The length of the article is 953 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Group therapy can improve viral load in HIV.(Infectious Diseases) Author: Damian McNamara Publication: Internal Medicine News (Magazine/Journal) Date: February 15, 2005 Publisher: International Medical News Group Volume: 38 Issue: 4 Page: 67(1) Distributed by Thomson...